Multidisciplinary approach in breast cancer

• Autor(a) principal: Ana Maria de Araújo Martins
• Data de Publicação: 2013
• Outros Autores: Ana Cristina Dias de Paiva, Debora Balabram, Gilvane Naves Marcondes Goulart, Larissa Oliveira de Aquino, Mayne Cardoso Cani, Thais Vilela de Pinho Andrade, Carolina Patricia Mendes Rutkowsk, Leandro Goncalves Alves Ramos, Juliana Silva Barra, Eliza Maria de Freitas Range, Kelly Cristina Reis, Ana Silvia Diniz Makluf, Soraia Martins de Araujo, Carolina de Oliveira Barra, Priscilla Duraes Bicalho, Aloma de Fatima Campos Morici, Annamaria Massahud Rodrigues Dos Santos
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Institucional da UFMG
• Texto Completo: http://hdl.handle.net/1843/57274
• topic: Breast cancer; Multidisciplinary team; Neoplasias Inflamatórias Mamárias; Equipe de Assistência ao Paciente

Background: A multidisciplinary team (MDT) approach to breast cancer management is the gold standard. The aim is to evaluate MDT decision making in a modern breast unit.Methods: All referrals to the breast MDT where breast cancer was diagnosed from 1 July 2009 to 30 June 2011 were included.Multidisciplinary team decisions were compared with subsequent patient management and classified as concordant or discordant.Results: Over the study period, there were 3230 MDT decisions relating to 705 patients. Overall, 91.5% (2956 out of 3230) of decisions were concordant, 4.5% (146 out of 3230), were discordant and 4% (128 out of 3230) had no MDT decision. Of 146 discordant decisions, 26 (17.8%) were considered ‘unjustifiable’ as there was no additional information available after the MDT to account for the change in management. The remaining 120 discordant MDT decisions were considered ‘justifiable’, as management was altered due to patient choice (n ¼ 61), additional information available after MDT (n ¼ 54) or MDT error (n ¼ 5). Conclusion: The vast majority of MDT decisions are implemented. Management alteration was most often due to patient choice or additional information available after the MDT. A minority of management alterations were ‘unjustifiable’ and the authors recommend that any patient whose treatment is subsequently changed should have MDT rediscussion prior to treatment.